{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:25:12Z","timestamp":1793805912965,"version":"4.6.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.urolonc.2026.06.021","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:04:21Z","timestamp":1784088261000},"page":"412-421","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinicopathological features and prognosis of plasmacytoid urothelial carcinoma of the bladder: A retrospective analysis of 36 cases"],"prefix":"10.1016","volume":"44","author":[{"given":"Xueping","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kui","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqiang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.urolonc.2026.06.021_bib0001","first-page":"32","article-title":"News in the classification of WHO 2022 bladder tumors","volume":"115","author":"Raspollini","year":"2022","journal-title":"Pathologica"},{"issue":"3","key":"10.1016\/j.urolonc.2026.06.021_bib0002","first-page":"277","article-title":"Plasmacytoid transitional cell carcinoma. Report of a case with initial presentation mimicking multiple myeloma","volume":"35","author":"Sahin","year":"1991","journal-title":"Acta Cytol"},{"key":"10.1016\/j.urolonc.2026.06.021_bib0003","article-title":"Molecular characterization of plasmacytoid urothelial carcinoma and the impact on treatment implications","volume":"37","author":"Weiss","year":"2023","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.urolonc.2026.06.021_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2024.04.012","article-title":"Plasmacytoid urothelial carcinoma of the urinary bladder-a clinicopathological and molecular analysis of 52 cases","volume":"148","author":"Zheng","year":"2024","journal-title":"Hum Pathol"},{"issue":"7","key":"10.1016\/j.urolonc.2026.06.021_bib0005","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41585-023-00847-7","article-title":"Molecular profile of bladder cancer progression to clinically aggressive subtypes","volume":"21","author":"Guo","year":"2024","journal-title":"Nat Rev Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.021_bib0006","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/bco2.108","article-title":"Outcomes of poorly differentiated and plasmacytoid variant bladder urothelial carcinoma","volume":"3","author":"Lockhart","year":"2022","journal-title":"BJUI Compass"},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.021_bib0007","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3233\/BLC-190258","article-title":"Plasmacytoid urothelial carcinoma: response to chemotherapy and oncologic outcomes","volume":"6","author":"Diamantopoulos","year":"2020","journal-title":"Bladder Cancer (Amsterdam, Netherlands)"},{"issue":"7","key":"10.1016\/j.urolonc.2026.06.021_bib0008","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/s41416-020-01244-2","article-title":"Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma","volume":"124","author":"Teo","year":"2021","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.urolonc.2026.06.021_bib0009","first-page":"1001","article-title":"[Clinical pathological expert consensus on HER-2 testing in urothelial carcinoma in China]","volume":"43","year":"2021","journal-title":"Zhonghua Zhong Liu za Zhi [Chin J Oncol]"},{"issue":"17","key":"10.1016\/j.urolonc.2026.06.021_bib0010","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16173050","article-title":"Evaluating treatment patterns and the role of neoadjuvant chemotherapy in plasmacytoid urothelial carcinoma: insights from a combined national and institutional series","volume":"16","author":"Rahman","year":"2024","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.021_bib0011","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3390\/biomedicines13010086","article-title":"Advances in therapy for urothelial and non-urothelial subtype histologies of advanced bladder cancer: from etiology to current development","volume":"13","author":"Kwon","year":"2025","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.urolonc.2026.06.021_bib0012","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/JU.0000000000000794","article-title":"Plasmacytoid variant urothelial carcinoma of the bladder: a systematic review and meta-analysis of clinicopathological features and survival outcomes","volume":"204","author":"Kim","year":"2020","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.06.021_bib0013","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.urology.2013.12.035","article-title":"Plasmacytoid bladder cancer: variant histology with aggressive behavior and a new mode of invasion along fascial planes","volume":"83","author":"Kaimakliotis","year":"2014","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.021_bib0014","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s42047-020-0056-5","article-title":"Plasmocytoid urothelial carcinoma - clinical, histological, immunohistochemical and molecular aspects","volume":"3","author":"Leite","year":"2020","journal-title":"Surg Exp Pathol"},{"key":"10.1016\/j.urolonc.2026.06.021_bib0015","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.humpath.2019.04.012","article-title":"Plasmacytoid\/diffuse urothelial carcinoma: a single-institution immunohistochemical and molecular study of 69 patients","volume":"90","author":"Perrino","year":"2019","journal-title":"Hum Pathol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.06.021_bib0016","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/ng.3503","article-title":"Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer","volume":"48","author":"Al-Ahmadie","year":"2016","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.urolonc.2026.06.021_bib0017","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/modpathol.2010.187","article-title":"E-cadherin expression in plasmacytoid, signet ring cell and micropapillary variants of urothelial carcinoma: comparison with usual-type high-grade urothelial carcinoma","volume":"24","author":"Lim","year":"2011","journal-title":"Modern Pathol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.021_bib0018","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of Trastuzumab Deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 Phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.06.021_bib0019","first-page":"390","article-title":"A case report of a patient with plasmacytoid urothelial cancer with significant response to HER2-targeting therapy and enfortumab vedotin","volume":"9","author":"Sun","year":"2021","journal-title":"Am J Clin Exp Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.06.021_bib0020","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/JU.0000000000003836","article-title":"Impact of divergent differentiation and\/or histological subtype of urothelial carcinoma on patient outcomes in the GETUG-AFU V05 VESPER trial","volume":"211","author":"Allory","year":"2024","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.06.021_bib0021","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.juro.2011.10.145","article-title":"Plasmacytoid carcinoma of the bladder: a urothelial carcinoma variant with a predilection for intraperitoneal spread","volume":"187","author":"Ricardo-Gonzalez","year":"2012","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.06.021_bib0022","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1016\/j.juro.2012.11.084","article-title":"Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis","volume":"189","author":"Dayyani","year":"2013","journal-title":"J Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T14:26:10Z","timestamp":1793802370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926005776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1078143926005776"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.06.021","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinicopathological features and prognosis of plasmacytoid urothelial carcinoma of the bladder: A retrospective analysis of 36 cases","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.06.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}